Tectonic Therapeutic to Present Phase 1a Data at AHA 2024

Tectonic Therapeutic, Inc. (NASDAQ: TECX), a biotechnology company in its clinical stage, focuses on discovering and developing therapeutic proteins and antibodies that modulate G-protein coupled receptors (GPCRs). On October 22, 2024, the company announced an upcoming presentation at the American Heart Association (AHA) 2024 conference. The presentation will showcase Phase 1a data for their leading asset, TX000045 (TX45), a long-acting relaxin. This drug is being developed as a potential best-in-class therapy for patients suffering from Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF). The company had previously announced topline results from the study on September 19, 2024.

The AHA 2024 Presentation, scheduled from November 16-18, 2024, in Chicago, Illinois, will include a poster titled "The tolerability, safety, pharmacokinetics, and pharmacodynamics of TX000045, a long-acting Fc-relaxin fusion protein after single doses in healthy volunteers." Dr. Marcella K. Ruddy, the Chief Medical Officer, will present this data. The session named "A Medley of All Things Pulmonary Hypertension" will take place on November 16, 2024, from 2:00 PM to 3:00 PM CDT / 3:00 PM to 4:00 PM EDT.

TX45 is an Fc-relaxin fusion protein with optimized pharmacokinetics and biophysical properties. It activates the RXFP1 receptor, the GPCR target of the hormone relaxin. Relaxin is a naturally occurring protein in humans, usually expressed at low levels. During pregnancy, relaxin levels increase, causing vasodilation, reducing both systemic and pulmonary vascular resistance, and increasing cardiac output to meet the increased demand for oxygen and nutrients. Relaxin also has anti-fibrotic effects on pelvic ligaments, aiding in childbirth.

Tectonic is currently evaluating TX45 in an ongoing Phase 1b hemodynamic proof-of-concept study and a Phase 2 clinical proof-of-concept study, both in patients with PH-HFpEF.

Group 2 Pulmonary Hypertension in HFpEF is a condition defined by the World Health Organization (WHO) as one of five groups of pulmonary hypertension (PH). This subtype results from left-sided heart disease, specifically pulmonary hypertension secondary to left heart failure with preserved ejection fraction (PH-HFpEF). Patients with PH-HFpEF experience chronic heart failure that increases blood pressure in the pulmonary arteries, which in turn heavily strains the right side of the heart. This increased pressure leads to diminished exercise capacity, shortness of breath, and eventually right-sided heart failure, often resulting in death. Currently, there are no approved medications specifically for Group 2 PH, although several Group 1 PH (Pulmonary Arterial Hypertension, PAH) medications have been tested without success.

Tectonic Therapeutic, headquartered in Watertown, Massachusetts, leverages its proprietary GEODe™ (GPCRs Engineered for Optimal Discovery) technology platform. The company aims to develop medicines that address the existing challenges in GPCR-targeted drug discovery. Their focus is on areas with significant unmet medical needs, where existing therapeutic options are poor or non-existent, thus aiming to improve patients' quality of life.